Patients with myelodysplastic syndrome/acute myeloid leukemia
Patients must not have treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or features suggestive of AML/MDS
Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML
Participants with a previously documented diagnosis of myelodysplastic syndrome (MDS) (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia
Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML
Patients with prior myelodysplastic syndrome or acute myeloid leukemia
Patients with hematologic malignancies (includes patients with myelodysplastic syndrome/acute myeloid leukemia)
Subjects with any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Participants with a history of myelodysplastic syndrome or acute myeloid leukemia
Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of \r\nmyelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).
Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), or features suggestive of MDS/AML
Known history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or myelodysplastic syndrome (MDS) in confirmed relapse based on bone marrow examination after allogeneic HCT; biopsy confirmed myeloid sarcoma or extramedullary AML may also be considered
A diagnosis or suspicion of myelodysplastic syndrome/acute myeloid leukemia.
Patient must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Known myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML)
Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML
Patients with myelodysplastic syndrome/acute myeloid leukemia
Patients with myelodysplastic syndrome/acute myeloid leukemia
Known history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
PHASE I: No features suggestive of myelodysplastic syndrome/ acute myeloid leukemia
PHASE II: No features suggestive of myelodysplastic syndrome/ acute myeloid leukemia
Patients with myelodysplastic syndrome/acute myeloid leukemia
Patients with the following diseases: acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) undergoing second or above allogeneic (allo)-stem cell transplant (SCT) using the same donor or different donor for disease relapse; patients with other hematologic malignancies, including acute lymphoblastic leukemia (ALL), will be at the discretion of the investigators with discussion with the principal investigator (PI)
Patients with biopsy-proven acute myeloid leukemia or myelodysplastic syndrome with persistent disease or in remission
Patients with biopsy-proven acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome in remission or relapse
History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic Syndromes (MDS)/acute myeloid leukemia (AML).
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Patients with myelodysplastic syndrome/acute myeloid leukemia
Patients with myelodysplastic syndrome(MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).
Participants with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
Subject has a diagnosis of primary acute myeloid leukemia (AML) or AML secondary to myelodysplastic syndrome (MDS) according to WHO classification () as determined by pathology review at the treating institute.
Known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Patients must not have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
No Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS
A history of other primary invasive malignancy that has not been in remission for at least  years or a current diagnosis of myelodysplastic syndrome (MDS) or an immature leukemia such as acute myeloid leukemia (AML)
Patients with myelodysplastic syndrome (MDS)/ treatment-related acute myeloid leukemia (t-AML) or with features suggestive of MDS/AML
Patients with one of the following diagnoses:\r\n* Acute myeloid leukemia (AML)\r\n* Acute lymphoblastic leukemia (ALL)\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Myelodysplastic syndrome (MDS)
Patients with myelodysplastic syndrome/acute myeloid leukaemia.
Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS. Prior allogeneic bone marrow transplant or double umbilical cord blood transplantation
Treatment Group B (TGB): Acute Leukemia (Part  - acute myeloid leukemia [AML] only), myelodysplastic syndrome (MDS), myelodysplastic /myeloproliferative neoplasms (MDS/MPN) and myelofibrosis (MF)
De novo or secondary acute myeloid leukemia (AML) (post myelodysplastic syndrome [MDS] or myeloproliferative neoplasm [MPN] or after leukemogenic chemotherapy) according to WHO  criteria For Part A:
Participant has a relapsed or refractory hematologic malignancy (with any measurable disease) with FLT-ITD or TKD mutations and one of the following diagnoses:\r\n* Acute myeloid leukemia (AML)\r\n* AML with prior myelodysplastic syndrome (MDS)\r\n* Myeloperoxidase (MPO)-positive mixed phenotype acute leukemia
Patient has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
Clonal cytogenetic abnormalities associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) on marrow examination
Acute leukemia patients (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], acute promyelocytic leukemia [APL], therapy-related myeloid neoplasm [tMN], high grade myelodysplastic syndrome [MDS])
Untreated de novo or secondary acute myeloid leukemia (AML), including AML that has progressed from myelodysplastic syndrome (MDS), and histologically documented diagnosis
Participants with a previously documented diagnosis of myelodysplastic syndrome (or any dysplastic leukocyte morphology suggestive of myelodysplastic syndromes [MDS]) or acute myeloid leukemia
Subjects with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS